Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$2.46 - $4.07 $25,465 - $42,132
10,352 New
10,352 $26,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $3.03 $20,777 - $33,487
11,052 New
11,052 $22,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $59.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.